Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1994-9-26
|
pubmed:abstractText |
Experimental and clinical tests carried out over the last few years have brought many new and important insights into the pathophysiology of the so-called high-altitude sickness. Overall, new, scientifically proven methods for the acute therapy of various forms of high-altitude sickness have been made, which can be used for medical practice. Azetazolamide: The clinical effectiveness and the improvement of the exchange of body gases seem to be, to a large extent, scientifically proven. Dexamethasone: Several scientifically controlled studies have proven the effectiveness of dexamethasone regarding the relief of symptoms mainly concerning cerebral high-altitude oedema. Controlled studies confirm a significant reduction of symptoms, compared to placebo methods, the effects vanishing after a 12-hour therapy. Nifedipine: The prescription of nifedipine for radiologically proven high-altitude oedema often leads to a clinical improvement, to an improved oxygenation, to a reduction of the alveolar-arterial oxygen gradient, as well as the pulmonary-arterial pressure and, thus, to a great extent, leads to progrediental oedema dissolution. However, in the practice of high-altitude hiking, this therapy has its natural limits and therefore must not lead to the neglection of prophylactics, which means, consistent acclimatisation regarding the classical rules of high-altitude hiking.
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acetazolamide,
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Furosemide,
http://linkedlifedata.com/resource/pubmed/chemical/Oxygen
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0043-5341
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
144
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
125-9
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:8073777-Acclimatization,
pubmed-meshheading:8073777-Acetazolamide,
pubmed-meshheading:8073777-Altitude Sickness,
pubmed-meshheading:8073777-Aspirin,
pubmed-meshheading:8073777-Calcium Channel Blockers,
pubmed-meshheading:8073777-Combined Modality Therapy,
pubmed-meshheading:8073777-Dexamethasone,
pubmed-meshheading:8073777-Furosemide,
pubmed-meshheading:8073777-Humans,
pubmed-meshheading:8073777-Hyperbaric Oxygenation,
pubmed-meshheading:8073777-Oxygen,
pubmed-meshheading:8073777-Physical Exertion
|
pubmed:year |
1994
|
pubmed:articleTitle |
[Etiology, clinical aspects and therapy of altitude sickness].
|
pubmed:affiliation |
Institut für Sportwissenschaften, Universität Salzburg.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|